ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals focuses on developing medicines for CNS disorders and rare diseases. The company offers NUPLAZID for Parkinsons disease psychosis and DAYBUE for Rett Syndrome treatment. ACP-101 is being developed for Prader-Willi syndrome, while ACP-204 targets Alzheimers disease psychosis. ACP-2591 is in Phase I for Rett syndrome and Fragile X syndrome. The company has license agreements with Neuren Pharmaceuticals and Stoke Therapeutics to develop RNA-based medicines. ACADIA was formerly known as Receptor Technologies and changed its name in 1997.
Overview
Strengths
- Pricing power: gross margin has held between 91% and 96% over the last 6 years (latest 91.7%).
- Valued below its Biotechnology peers: P/E 9.2x vs. a median of 20.4x.
- Consistent growth: revenue has compounded at 21.1% a year over 6 years, rising every year.
- Cheaper than its own history: P/E 9.2x vs. a historical average of 75.2x.
Weaknesses
- Our discounted cash flow model finds no value to support the current price: projected cash flows do not cover its debt and current valuation.
- Unreliable cash generation: free cash flow was negative in 4 of the last 7 years.
- Unstable profitability: operating margin ranged from -73% to 10% over the last 7 years, with operating losses in 5 of them.
- Valued at a premium to its Biotechnology peers: P/FCF 34.4x vs. a median of 18.8x and EV/EBITDA 29.9x vs. a median of 15.0x.
- Earnings quality red flag: reported profit exceeds operating cash flow by 18.0% of total assets.
- Earnings are projected to decline (-10.0% per year).
Key Financial Data